Related Experiment Video

Updated: May 4, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.5K

Off-Target Effects of BCR-ABL and JAK2 Inhibitors

Myke R Green1, Michael D Newton, Karen M Fancher

  • 1*Division of Hematology/Oncology, University of Arizona Cancer Center †Department of Pharmacy Services, University of Arizona Medical Center, Tucson, AZ ‡Department of Clinical Pharmacy, West Virginia University School of Pharmacy §Department of Pharmacy, West Virginia University Hospitals, Morgantown, WV ∥Department of Pharmacy Practice-Oncology Acute Care, Duquesne University Mylan School of Pharmacy, Pittsburgh, PA.

American Journal of Clinical Oncology
|December 20, 2013
PubMed

Insights

Targeted oncolytic agents, like tyrosine kinase inhibitors, have transformed cancer treatment, especially for myeloproliferative neoplasms (MPN). Understanding their off-target effects is key to optimizing therapy and predicting patient outcomes.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Targeted oncolytic agents, particularly tyrosine kinase inhibitors (TKIs), have revolutionized cancer therapy.
  • TKIs targeting BCR-ABL and JAK2 have significantly improved outcomes for myeloproliferative neoplasms (MPN).

Purpose of the Study:

  • To explore the clinical implications of off-target effects of TKIs used in MPN treatment.
  • To provide clinicians with insights for selecting optimal pharmacotherapy and predicting toxicities.

Main Methods:

  • Review of existing literature on TKI mechanisms of action and off-target effects.
  • Analysis of clinical trial data and pharmacodynamic studies related to MPN therapies.

Main Results:

  • Clinically relevant doses of TKIs inhibit multiple tyrosine kinases beyond their primary targets.
  • These off-target effects are associated with both the efficacy and toxicity of these agents.
  • Understanding these effects can guide treatment decisions and identify potential new indications.

Conclusions:

  • Knowledge of off-target binding and signaling pathway effects is crucial for effective TKI utilization in MPN.
  • This understanding empowers clinicians to personalize pharmacotherapy, anticipate adverse events, and expand TKI applications.
  • Further research into off-target profiles can enhance rational drug development and clinical practice.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.5K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

7.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K